Name of journal: *World Journal of Dermatology*

ESPS Manuscript NO: 14416

Columns: MINIREVIEW

**Primary cutaneous B cell lymphoma: Clinical features, diagnosis and treatment**

Yilmaz F *et al.* Primary cutaneous B cell lymphoma

Fergun Yilmaz, Nur Soyer, Filiz Vural

**Fergun Yilmaz, Nur Soyer, Filiz Vural,** Department of Hematology,Ege University, 35100 Izmir, Turkey

**Author contributions:** Yilmaz F, Soyer N and Vural F contributed to this paper.

**Conflict-of-interest:** The authors declare no conflict of interest.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Correspondence to: Filiz Vural, MD,** Department of Hematology, Ege University Hospital, Bornova, 35100 Izmir, Turkey. fivural@yahoo.com

**Telephone:** +90-23-23904541

**Received:** October 2, 2014

**Peer-review started:** October 3, 2014

**First decision:** November 27, 2014

**Revised:** December 18, 2014

**Accepted:** Janurary 9, 2015

**Article in press:**

**Published online:**

**Abstract**

Primary cutaneous B cell lymphoma (PCBCL) is defined as B cell lymphomas that presents in the skin without any evidence of extra-cutaneous involvement at diagnosis. They are the second most common type of primary cutaneous lymphomas accounting for 25%-30%. Since the prognosis and treatment differ from systemic lymphomas involving the skin, differential diagnosis is very important. PCBCL is a heterogeneous group of disease comprising different B cell lymphomas with distinct treatment and prognosis. PCBCL is divided into 5 subclasses according to World Health Organization and European Organization of Research and Treatment of Cancer classification. Primary cutaneous marginal zone lymphoma and primary cutaneous follicle centre lymphoma are indolent forms and often confined to skin at presentation and during the course of the disease. But primary cutaneous diffuse large B cell lymphoma, leg type and intravascular large B cell lymphoma are more aggressive forms that may disseminate to extra-cutaneous tissues. There is not a treatment consensus since they are rare entities. Local therapies like radiotherapy, surgery or intralesional steroids are options for localized disease in indolent forms. More disseminated disease may be treated with a systemic therapy like single agent rituximab. However combination chemotherapies which are used in systemic lymphomas are also required for aggressive PCBCL. Although indolent forms have relatively better prognosis, early relapses and disseminated diseases are mostly observed in aggressive form with a consequent poor prognosis.

**Key words:** Primary cutaneous lymphomas; Diagnosis; Treatment; Bcell lymphoma

© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** Primary cutaneous B cell lymphoma is a type of lymphoma that presents in the skin without evidence of extra-cutaneous involvement. Prognosis and treatment being different from systemic lymphomas involving the skin makes differential diagnosis very important. It is a heterogeneous group of diseases that consists of indolent (primary cutaneous marginal zone lymphoma, primary cutaneous follicle centre lymphoma) and aggressive forms (primary cutaneous diffuse large B cell lymphoma, leg type and intravascular large B cell lymphoma). The indolent forms are mostly confined to the skin and have good prognosiswhereas aggressive forms presentwith disseminated disease and are treated mostly with systemic combination chemotherapies.

Yilmaz F, Soyer N, Vural F.Primary cutaneous B cell lymphoma: Clinical features, diagnosis and treatment. *World J Dermatol* 2015; İn press

**INTRODUCTION**

Primary cutaneous lymphomas (PCL) are areneoplastic proliferation of lymphocytes in the skin. They are the second most common extranodalnon-Hodgkin lymphomas. PCL can bedivided into two main groups; primary cutaneous T cell lymphoma and primary cutaneous B cell lymphoma (PCBCL).

PCBCL is defined as B cell lymphomas that present in the skin without any evidence of extra-cutaneous involvement at diagnosis. They are the second most common type of PCL, accounting for 25%-30%[1-5]. Since the prognosis and treatment differ from systemic lymphomas involving the skin, differential diagnosis becomes crucial.

PCBCL is a heterogeneous group of diseases consisting different B cell lymphomas with distinct treatment and prognosis. Their clinical presentation is relatively uniform, mostly manifested by nodules (Figure 1). The indolent forms, primary cutaneous marginal zone lymphoma (PCMZL) and primary cutaneous folliclecentrelymphoma (PCFCL) are often confined to the skin during the course of the disease. Although all body parts can be affected, specific distribution of the subtypes may provide information for differential diagnosis[6].

**CLASSIFICATION**

PCBCL are divided into 5 subclasses according to World Health Organization and European Organization of Research and Treatment of Cancer (WHO – EORTC) classification[2] (Table 1).

In WHO classification of tumours of hematopoietic and lymphoid tissues, primary cutaneous diffuse large B cell lymphoma, leg type (PCLBCL-LT) is classified under the heading of diffuse large B cell lymphoma not otherwise specified, NOS. PCFCL and intravascular large B cell lymphoma (IVL) are considered specific entities. PCMZL can be classified under the heading of extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma)[7].

**DIAGNOSIS AND INITIAL EVALUATION**

Thoroughphysical examination including theinspection of all the parts of the skin and detailed history giving special attention to B symptoms (weight loss, fever, night sweats), laboratory tests including serum antibodies or polymerase chain reaction based analysis for bacterial aetiologies should be performed. An adequate biopsy of the lesion, preferably excisional biopsy or a punch biopsy of at least 4mm for routine histology and immunohistology is crucial for the diagnosis of CL (Figures 2 and 3). Pathological lymph nodes should be biopsied for possible involvement. Bone marrow aspiration and biopsy (BMA/B) is optional for most of the PCBCL with indolent course but is required in more aggressive CL like PCLBCL-LT and IVL[6,8-10]. However, differentiating early stage and rare variants of PCL from benign lymphoproliferative diseases can sometimesbe complicated. Molecular analysis by demonstrating the clonality of B cells is an option[11]. Demonstration of monoclonal rearrangement of immunoglobulin by polymerase chain reaction (PCR) is a useful diagnostic tool when used in conjunction with data from the clinician and pathologist. Flowcytometryimmunophenotyping is also a feasible and reliable method for detecting clonality in PCBCLs and can provide additional prognostic and therapeutic information[12]. Radiologic examinations [chest X-ray, ultrasonography, computed tomography (CT), and positron emission tomography combined with computed tomography (PET/CT)] are contributory tools to exclude skin involvement of a systemic lymphoma[6].

**STAGING**

TNM classification for cutaneous lymphomas other than mycosis fungoides and Sezary syndrome was established by International Society for Cutaneous Lymphomas (ISCL) and Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer (EORTC) in 2007 (Table 2). However this classification does not give much information about the prognosis and survival[8,13].

**PRIMARY CUTANEOUS MARGINAL ZONE LYMPHOMA**

PCMZL is an indolent B cell lymphoma characterized by infiltration by acombination ofsmall B cells, marginal zone cells, lymphoplasmacytoid cells, and plasma cells[2]. According to WHO classification it is listed under the heading of extranodal marginal zone lymphoma of MALT lymphoma[7]. Cases formerly known as “immunocytoma” as well as “nonmyelomatous plasmacytomas” of skin are now included in this category. It makes up approximately 7% of all CL[13,14]. It is mostly presented asred to violaceousnodulessometimes surrounded by an erythematous halo,mainly on the trunk and extremities although papules and plaques have also been reported[2,6].Lesions may be solitary (51%), localized (26%), or multifocal (23%)[14]. It usually presents in the fifth or six decade and more common in men thanwomen[14]. Extra-cutaneous involvement at the time of diagnosis and dissemination to extra-cutaneous sites are uncommon butrecurrence in the skin is frequent[14]. Elevated lactate dehydrogenase, beta-2-microglobulin levels, abnormal complete blood count values and B symptoms are uncommon and considered as clues for a systemic disease[14].

Although there is no clearly identified risk factor or hereditary tendency, associations with infectious agents,especially Borrelia burgdorferi, and autoimmune diseases have been reported.A link between the PCBCL and Borrelia burgdorferihas been documented in some studies in Europe and healing of the lesion with antibiotic treatment has been reported by some researchers. However, this could not be confirmed by other studies carried out especially in the United States and Asia[15-21].

The diagnosis of the disease can be established by histopathologic examination of the skin biopsy and exclusion of a systemic disease. Excisional biopsy is preferred but if an excisional biopsy is not appropriate, it can be substituted by a punch biopsy of an adequate length[9]. Morphologically, skin biopsy specimens depict nodular to diffuse infiltrates with sparing of the epidermis[2,21].

The differentiation of PCMZL from reactive skin changes and other cutaneous lymphomas is important. Morphologic and immunophenotypic features and demonstration of clonality will aid in the differential diagnosis.

***Treatment***

Treatment depends on the symptoms of the patient, stage of the disease and the number of the lesions. The treatment options include antibiotics, rituximab, chemotherapy, intralesional interferon alfa, radiotherapy and excision.

Radiotherapyis a rational option especially for patients with solitary lesion or a few lesions that can be treated in one radiotherapy field[6,22-25]. The margins of the radiation field should be clinically free of the disease[6]. With local radiotherapy, complete remission (CR) and 5 year disease specific survival (DSS) rates are over 95%[6,22,24]. Even though approximately half of the patients experience cutaneous relapses,extra-cutaneous relapses are very rare.

Surgery is used frequently in patients with local lesion. CR rate is nearly 100% but skin relapses are not so uncommon[6]. In an Italian study, CR and relapse rates were reported as 97.4% and 31.6%, respectively. In the same study, 97.6% of the PCMZL patients achieved CR and 46.9% of them had relapse after radiotherapy[24].

Topical steroids, triamcinolone, nitrogen mustard and cryotherapy are other local therapies with good responses[13,25,26]. Intralesional interferon treatment is another alternative strategy. In small case series of 8 patients, CR was 100% but two of them relapsed and second CR was achieved with another cycle of IFN alpha[25,27]. There is very limited data on intralesional[28] or systemic rituximab[29] treatment. Three of 5 patients achieved complete (1 patient) and partial (2 patients) responses[29]. Although the experience with rituximab is very limited it can be an alternative treatment option.Treatments with chemotherapy with a single agent such as chlorambucil or combination of medications have also been reported in the literature, especially in multifocal diseases. The response rates are relatively good in patients withdisseminated disease[6,25]. In asymptomatic patients with disseminated disease a close follow up/wait-and-see strategy and treatment of only symptomatic lesions can also be performed.

A trial with an antibiotic treatment may be a rational option for B. *burgdoferi* positive patients before more aggressive therapies[6,25].

**PRIMARY CUTANEOUS FOLLICLE CENTRE LYMPHOMA**

It is a tumour of neoplastic follicle centre cells, centrocytes andcentroblasts. Itis the most common type of PCBCL, accounting about two thirds of all cases[30]. It typically presents with solitary or multiple firm, erythematous, painless, papules, plaques, or tumours in middle ages with a slight predominance in males. It has a predilection for the head, neck, and trunk. Multifocal presentation is a rare entity[2,24,31]. It is an indolent lymphoma with a very slow progression rate and long latent period[32]. Extra-cutaneous dissemination is a rare, justlike PCMZL cases.

The diagnosis is based on the histological and immunohistochemical examination of biopsy material and ruling out the systemic disease. Primary cutaneous follicle centre lymphoma (PCFCL) shows nodular or diffuse infiltration of the dermis and subcutaneous tissue; sparing of the epidermis is almost a rule. Microscopically, typically large, often multilobulated centrocytes and large centroblasts with prominent nucleoli in variable numbers are present[6]. Tumours show 3 different growth patterns; follicular, follicular and diffuse (mixed) and diffuse.

Differential diagnosis from systemic lymphomas and reactive follicular hyperplasia is critical since the treatment and prognosis are completely different. Strong expression of Bcl-2, Bcl-6, and CD10 and t(14,18) should raise the suspicion of systemic follicular lymphoma with skin involvement[33]. Unlike the follicles seen in cutaneous follicular hyperplasia, the follicles in PCFCL are ill-defined, have a decreased mantle zone and lack tingible body macrophages.

According to ISCL/EORTC guidelines, bone marrow evaluation is optional for staging in PCFCL[13]. However, bone marrow involvement is demonstrated in 11% of the patients with PCFCL presenting in the skin. Among them, bone marrowwas the only extracutaneous involvement in 9 patients. Their prognosis is worse in comparison to patients presenting only with skin involvement[34]. Although there is not a consensus, these results indicate that BMB/A should be included in the staging system in PCFCL patients presenting with skin lesions[6,34].

**TREATMENT**

Surgery and radiotherapy are the first line treatment options for single or localized lesions. Multifocal lesions can be treated with many different modalities including radiotherapy, intralesional or local therapies. Close follow up and observation may also be an option in asymptomatic patients since it is a very slowly progressive disease.

In patients presenting with solitary or localized skin lesions, radiation therapy covering also the clinically normal margins around the lesion is the preferred mode of treatment[9]. Although radiotherapy is mostly preferred in patients with solitary or localized disease, multifocal disease can also be treated with radiotherapy[35]. PCFCL is highly sensitive to radiotherapy with a 99% CR rate and 100% 5 year over-all survival[9,36]. Solitary lesions that are small and well-demarcated can be treated with surgical excision but relapse rate is as high as 40% after excision[9]. Other local treatment options with good results are topical or intralesional steroids, cryotherapy, intralesional interferon alpha[9,27,37].

In patients with very extensive skin lesions, systemic rituximab is the ﬁrst choice of treatment. Rituximab, systemic or intralesional, have been used in limited number of patients with PCFCL in the literature. CR has been achieved in 10/11 PCFCL patients treated with systemic rituximab while 3 patients had relapse after achieving CR[38]. Intralesional rituximab also have similar effectiveness that is confirmed only in small number of cases[9,39].

Combination chemotherapy should be considered only in patients with progressive and disseminated disease orpatients with large tumour burden who do not respond to other treatment modalities[9,23,25]. Almost one third of the patients had relapse after an initial treatment and most of the relapses occurred in the skin and can be treated with the initial treatment strategy. Dissemination to extra-cutaneous sites is uncommon[9]. Even though it is an indolentlymphoma, lesions presenting in the leg has poorer prognosis and these lesions should be treated more aggressively[9].

**PRIMARY CUTANEOUS LARGE B CELL LYMPHOMA, LEG TYPE**

Primary cutaneous large B cell lymphoma, leg type (PCLBCL –LT) is a PCBCL with predilection to legs that is histologically characterized by infiltration bycentroblasts and immunoblasts. It is classically a disease of patients in their seventies with a female predominance[7]. It mostly occurs on legs unilaterally or bilaterally but, less than one third of the patients may present with lesionsin an area other than the leg[2,6,40,41]. The prognosis is worse compared to other PCBCLs with higher relapse rates of extra-cutaneous dissemination. Rapidly growing red or red to bluish skin lesion especially on the lower leg is typical[2,30,40].

The differential diagnosis especially from PCFCL is important;PCFCL typically comprises centrocytes which don’t express bcl2 or MUM1 in contrast to PCLBCL - LT. The site of presentation is also different since PCFCL has a predilection to trunk and head.

In contrast to indolent cutaneous lymphomas, BMB/A should be examined before initiating the therapy to exclude a systemic involvement.

Nearly all of the PCBCL-LT cases have at least one genetic alteration and half of them have combined several alterations. These mutations support lymphomagenesis with NF-κB activationand guide for targetted therapis[42].

***Treatment***

PCLBCL - LT is a more aggressive disease with extra-cutaneous progression, lower remission and higher relapse rates[24,41]. Multiple skin lesions, bcl-2 expression, are independent prognostic factors inthese patients[43]. Patients whopresentswith multiple lesions on the leg has worse prognosis than lesions on other sites or single lesions[43]. Another factor with a high prevalence associated with poor prognosis in PCLBCL – LT patients is MYD88L265Pmutation[44]. This mutation activates the nuclear factor-κB pathway and is associated with shorter survival rates. Patients harboring this mutation will be candidates for new targeted therapies in the future[44].

Localdisease control methods like radiotherapy or topical treatment are not effective in PCLBCL – LT patients. Five year overall survival and disease free survival have been calculated as 67% and 33%, respectively, when treated with radiotherapy[36]. Morethan half of the patients relapse after RT[9]. Radiotherapy is an option as a palliative regimenespecially in elderly patients who cannot be treated with systemic therapies[6,25].

Single agent rituximab is a reasonable therapy for elderly who can’t tolerate combination chemotherapies. In a retrospective analysis of 60PCLBCL – LT patients, all but one patient achieved CR (91.6%), with a 2 year survival of 81%when treated with combination chemotherapies plus rituximab. Two year survival rate was 59% in the groupof patients who were treated with other therapies and CR rate was 62%[41].

Similar to systemic diffuse large B cell lymphomas, PCLBCL – LT should be treated with antracyclin based combination chemotherapies with or without rituximab. RT can supplement systemic chemotherapies. RCHOP ± rituximab should be considered as first line chemotherapy[2,9,41]. Since large randomized clinical trials are lacking, the efficacy of the treatment options are not well documented.

Primary cutaneous DLBCL others, are lymphomas rather than DLBCL-LT[2]. It is a rare entity including morphologic variants of diffuse large B-cell lymphoma, such as anaplastic or plasmoblastic subtypes or T-cell/histiocyte rich large B-cell lymphomas and [2] intravascular large B cell lymphoma cutaneous variant.

**INTRAVASCULAR LARGE B CELL LYMPHOMA**

Intravascular large cell lymphoma (ILCL) is a rare subtype of large cell lymphoma that is characterized by the proliferation of lymphoma cells within the lumina of small blood vessels. They are more common in elderly patients, witha predilection to central nervous system and skin[2,45-47]. It has poor prognosis. The diagnosis is difficult because of divergent clinical presentation and absence of lymphadenopathy. Random skin biopsy is beneficial for early diagnosis in ILCL[48].

Cutaneous variant of the disease presents with nodules, plaques, or maculesin younger female patients[47]. The clinical presentation is diverse with painful, indurate, erythematous eruption, poorly circumscribedplaques, large solitary plaques, painful blue-red palpable nodules, tumours, ulcerated nodules, small red palpable spots, and erythematous and desquamated plaques. Lesions may be single or multiple,mostly on the leg, thigh and trunk[47]. Pain and oedema usually accompany the lesions. The differential diagnosis from inflammatory diseases and erythema nodosum is critical.

Patientsmostly presentwith a disseminated disease even though there are also cases with lesions confined to the skin only. Blood vessels are filled with neoplastic B cells that cause occlusion of the venules, capillaries and arterioles. Immunophenotypically, the neoplastic cells are mature B cells but rarely T cell phenotype can be seen[47]. B symptoms and bone marrowinvolvement are less common in cutaneous variant. Cutaneous variant has a better prognosis with a 3 year survival of 56% and better performance status[47]. Multiagent chemotherapies are the preferred therapies in these patients[9].

**REFERENCES**

1 **Zackheim HS**, Vonderheid EC, Ramsay DL, LeBoit PE, Rothfleisch J, Kashani-Sabet M. Relative frequency of various forms of primary cutaneous lymphomas. *J Am Acad Dermatol* 2000; **43**: 793-796 [PMID: 11050582]

2 **Willemze R**, Jaffe ES, Burg G, Cerroni L, Berti E, Swerdlow SH, Ralfkiaer E, Chimenti S, Diaz-Perez JL, Duncan LM, Grange F, Harris NL, Kempf W, Kerl H, Kurrer M, Knobler R, Pimpinelli N, Sander C, Santucci M, Sterry W, Vermeer MH, Wechsler J, Whittaker S, Meijer CJ. WHO-EORTC classification for cutaneous lymphomas. *Blood* 2005; **105**: 3768-3785 [PMID: 15692063]

3 **Dores GM**, Anderson WF, Devesa SS. Cutaneous lymphomas reported to the National Cancer Institute's surveillance, epidemiology, and end results program: applying the new WHO-European Organisation for Research and Treatment of Cancer classification system. *J Clin Oncol* 2005; **23**: 7246-7248 [PMID: 16192622]

4 **Park JH**, Shin HT, Lee DY, Lee JH, Yang JM, Jang KT, Ko YH. World Health Organization-European Organization for Research and Treatment of Cancer classification of cutaneous lymphoma in Korea: a retrospective study at a single tertiary institution. *J Am Acad Dermatol* 2012; **67**: 1200-1209 [PMID: 22521781 DOI: 10.1016/j.jaad.2012.02.033]

5 **Fujita A**, Hamada T, Iwatsuki K. Retrospective analysis of 133 patients with cutaneous lymphomas from a single Japanese medical center between 1995 and 2008. *J Dermatol* 2011; **38**: 524-530 [PMID: 21352297 DOI: 10.1111/j.1346-8138.2010.01049.x.PMID: 21352297]

6 **Kempf W**, Kazakov DV, Mitteldorf C. Cutaneous lymphomas: an update. Part 2: B-cell lymphomas and related conditions. *Am J Dermatopathol* 2014; **36**: 197-208; quiz 209-10 [PMID: 24658377 DOI: 10.1097/DAD.0b013e318289b20e]

7 **Swerdlow SH,** Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW. World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press, 2008

8 **Klemke CD**. Cutaneous lymphomas. *J Dtsch Dermatol Ges* 2014; **12**: 7-28; quiz 29-30 [PMID: 24393310 DOI: 10.1111/ddg.12237PMID: 24393310]

9 **Senff NJ**, Noordijk EM, Kim YH, Bagot M, Berti E, Cerroni L, Dummer R, Duvic M, Hoppe RT, Pimpinelli N, Rosen ST, Vermeer MH, Whittaker S, Willemze R. European Organization for Research and Treatment of Cancer and International Society for Cutaneous Lymphoma consensus recommendations for the management of cutaneous B-cell lymphomas. *Blood* 2008; **112**: 1600-1609 [PMID: 18567836 DOI: 10.1182/blood-2008-04-152850]

10 **Vural F**, Saydam G, Cagirgan S, Ertekin B, Hekimgil M, Unal I, Soydan S, Tombuloglu M. Primary cutaneous B-cell lymphoma: report of eight cases and review of the literature. *Int J Dermatol* 2008; **47**: 675-680 [PMID: 18613872 DOI: 10.1111/j.1365-4632.2008.03693.x]

11 **Möbs M**, Cerroni L, Flaig MJ, Lenze D, Hummel M, Assaf C. Molecular diagnostics in cutaneous lymphomas. *J Dtsch Dermatol Ges* 2013; **11** Suppl 4: 25-35 [PMID: 23721639 DOI: 10.1111/ddg.12084]

12 **Schafernak KT**, Variakojis D, Goolsby CL, Tucker RM, Martínez-Escala ME, Smith FA, Dittman D, Chenn A, Guitart J. Clonality assessment of cutaneous B-cell lymphoid proliferations: a comparison of flow cytometry immunophenotyping, molecular studies, and immunohistochemistry/in situ hybridization and review of the literature. *Am J Dermatopathol* 2014; **36**: 781-795 [PMID: 24335516 DOI: 10.1097/DAD.0000000000000022]

13 **Kim YH**, Willemze R, Pimpinelli N, Whittaker S, Olsen EA, Ranki A, Dummer R, Hoppe RT. TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer (EORTC). *Blood* 2007; **110**: 479-484 [PMID: 17339420]

14 **Servitje O**, Muniesa C, Benavente Y, Monsálvez V, Garcia-Muret MP, Gallardo F, Domingo-Domenech E, Lucas A, Climent F, Rodriguez-Peralto JL, Ortiz-Romero PL, Sandoval J, Pujol RM, Estrach MT. Primary cutaneous marginal zone B-cell lymphoma: response to treatment and disease-free survival in a series of 137 patients. *J Am Acad Dermatol* 2013; **69**: 357-365 [PMID: 23796549 DOI: 10.1016/j.jaad.2013.04.047]

15 **Li C**, Inagaki H, Kuo TT, Hu S, Okabe M, Eimoto T. Primary cutaneous marginal zone B-cell lymphoma: a molecular and clinicopathologic study of 24 asian cases. *Am J Surg Pathol* 2003; **27**: 1061-1069 [PMID: 12883238]

16 **Wood GS**, Kamath NV, Guitart J, Heald P, Kohler S, Smoller BR, Cerroni L. Absence of Borrelia burgdorferi DNA in cutaneous B-cell lymphomas from the United States. *J Cutan Pathol* 2001; **28**: 502-507 [PMID: 11737518]

17 **Ponzoni M**, Ferreri AJ, Mappa S, Pasini E, Govi S, Facchetti F, Fanoni D, Tucci A, Vino A, Doglioni C, Berti E, Dolcetti R. Prevalence of Borrelia burgdorferi infection in a series of 98 primary cutaneous lymphomas. *Oncologist* 2011; **16**: 1582-1588 [PMID: 22071292 DOI: 10.1634/theoncologist.2011-0108]

18 **Roggero E**, Zucca E, Mainetti C, Bertoni F, Valsangiacomo C, Pedrinis E, Borisch B, Piffaretti JC, Cavalli F, Isaacson PG. Eradication of Borrelia burgdorferi infection in primary marginal zone B-cell lymphoma of the skin. *Hum Pathol* 2000; **31**: 263-268 [PMID: 10685647]

19 **Cerroni L**, Zöchling N, Pütz B, Kerl H. Infection by Borrelia burgdorferi and cutaneous B-cell lymphoma. *J Cutan Pathol* 1997; **24**: 457-461 [PMID: 9331890]

20 **Takino H**, Li C, Hu S, Kuo TT, Geissinger E, Muller-Hermelink HK, Kim B, Swerdlow SH, Inagaki H. Primary cutaneous marginal zone B-cell lymphoma: a molecular and clinicopathological study of cases from Asia, Germany, and the United States. *Mod Pathol* 2008; **21**: 1517-1526 [PMID: 18820662 DOI: 10.1038/modpathol.2008.159]

21 **Cerroni L**, Signoretti S, Höfler G, Annessi G, Pütz B, Lackinger E, Metze D, Giannetti A, Kerl H. Primary cutaneous marginal zone B-cell lymphoma: a recently described entity of low-grade malignant cutaneous B-cell lymphoma. *Am J Surg Pathol* 1997; **21**: 1307-1315 [PMID: 9351568]

22 **Senff NJ**, Hoefnagel JJ, Neelis KJ, Vermeer MH, Noordijk EM, Willemze R. Results of radiotherapy in 153 primary cutaneous B-Cell lymphomas classified according to the WHO-EORTC classification. *Arch Dermatol* 2007; **143**: 1520-1526 [PMID: 18087001]

23 **Sokol L**, Naghashpour M, Glass LF. Primary cutaneous B-cell lymphomas: recent advances in diagnosis and management. *Cancer Control* 2012; **19**: 236-244 [PMID: 22710899]

24 **Zinzani PL**, Quaglino P, Pimpinelli N, Berti E, Baliva G, Rupoli S, Martelli M, Alaibac M, Borroni G, Chimenti S, Alterini R, Alinari L, Fierro MT, Cappello N, Pileri A, Soligo D, Paulli M, Pileri S, Santucci M, Bernengo MG. Prognostic factors in primary cutaneous B-cell lymphoma: the Italian Study Group for Cutaneous Lymphomas. *J Clin Oncol* 2006; **24**: 1376-1382 [PMID: 16492713]

25 **Suárez AL**, Querfeld C, Horwitz S, Pulitzer M, Moskowitz A, Myskowski PL. Primary cutaneous B-cell lymphomas: part II. Therapy and future directions. *J Am Acad Dermatol* 2013; **69**: 343.e1-34311; quiz 343.e1-34311; [PMID: 23957985 DOI: 10.1016/j.jaad.2013.06.011]

26 **Kennedy-Crispin M**, Myskowski PL. Cryotherapy for primary cutaneous B-cell lymphoma. *J Am Acad Dermatol* 2012; **67**: e292-e294 [PMID: 23158647 DOI: 10.1016/j.jaad.2012.07.010]

27 **Cozzio A**, Kempf W, Schmid-Meyer R, Gilliet M, Michaelis S, Schärer L, Burg G, Dummer R. Intra-lesional low-dose interferon alpha2a therapy for primary cutaneous marginal zone B-cell lymphoma. *Leuk Lymphoma* 2006; **47**: 865-869 [PMID: 16753871]

28 **Kyrtsonis MC**, Siakantaris MP, Kalpadakis C, Dimopoulou MN, Vassilakopoulos TP, Kontopidou FN, Antoniou C, Korkolopoulou P, Panayiotidis P, Pangalis GA. Favorable outcome of primary cutaneous marginal zone lymphoma treated with intralesional rituximab. *Eur J Haematol* 2006; **77**: 300-303 [PMID: 16856917]

29 **Morales AV**, Advani R, Horwitz SM, Riaz N, Reddy S, Hoppe RT, Kim YH. Indolent primary cutaneous B-cell lymphoma: experience using systemic rituximab. *J Am Acad Dermatol* 2008; **59**: 953-957 [PMID: 18817999 DOI: 10.1016/j.jaad.2008.08.005]

30 **Willemze R**, Kerl H, Sterry W, Berti E, Cerroni L, Chimenti S, Diaz-Peréz JL, Geerts ML, Goos M, Knobler R, Ralfkiaer E, Santucci M, Smith N, Wechsler J, van Vloten WA, Meijer CJ. EORTC classification for primary cutaneous lymphomas: a proposal from the Cutaneous Lymphoma Study Group of the European Organization for Research and Treatment of Cancer. *Blood* 1997; **90**: 354-371 [PMID: 9207472]

31 **Massone C**, Fink-Puches R, Laimer M, Rütten A, Vale E, Cerroni L. Miliary and agminated-type primary cutaneous follicle center lymphoma: report of 18 cases. *J Am Acad Dermatol* 2011; **65**: 749-755 [PMID: 21601947 DOI: 10.1016/j.jaad.2010.07.035]

32 **Bergman R**, Kurtin PJ, Gibson LE, Hull PR, Kimlinger TK, Schroeter AL. Clinicopathologic, immunophenotypic, and molecular characterization of primary cutaneous follicular B-cell lymphoma. *Arch Dermatol* 2001; **137**: 432-439 [PMID: 11295923]

33 **Hoefnagel JJ**, Vermeer MH, Jansen PM, Fleuren GJ, Meijer CJ, Willemze R. Bcl-2, Bcl-6 and CD10 expression in cutaneous B-cell lymphoma: further support for a follicle centre cell origin and differential diagnostic significance. *Br J Dermatol* 2003; **149**: 1183-1191 [PMID: 14674895]

34 **Senff NJ**, Kluin-Nelemans HC, Willemze R. Results of bone marrow examination in 275 patients with histological features that suggest an indolent type of cutaneous B-cell lymphoma. *Br J Haematol* 2008; **142**: 52-56 [PMID: 18422781 DOI: 10.1111/j.1365-2141.2008.07159.x]

35 **Bekkenk MW**, Vermeer MH, Geerts ML, Noordijk EM, Heule F, van Voorst Vader PC, van Vloten WA, Meijer CJ, Willemze R. Treatment of multifocal primary cutaneous B-cell lymphoma: a clinical follow-up study of 29 patients. *J Clin Oncol* 1999; **17**: 2471-2478 [PMID: 10561311]

36 **Smith BD**, Glusac EJ, McNiff JM, Smith GL, Heald PW, Cooper DL, Wilson LD. Primary cutaneous B-cell lymphoma treated with radiotherapy: a comparison of the European Organization for Research and Treatment of Cancer and the WHO classification systems. *J Clin Oncol* 2004; **22**: 634-639 [PMID: 14966086]

37 **Rubegni P**, De Aloe G, Pianigiani E, Lazzi S, Fimiani M. Primary cutaneous B-cell lymphoma: treatment with low dose intralesional recombinant interferon-alpha 2A. *J Eur Acad Dermatol Venereol* 1999; **12**: 70-71 [PMID: 10188159]

38 **Valencak J**, Weihsengruber F, Rappersberger K, Trautinger F, Chott A, Streubel B, Muellauer L, Der-Petrossian M, Jonak C, Binder M, Raderer M. Rituximab monotherapy for primary cutaneous B-cell lymphoma: response and follow-up in 16 patients. *Ann Oncol* 2009; **20**: 326-330 [PMID: 18836086 DOI: 10.1093/annonc/mdn636]

39 **Peñate Y**, Hernández-Machín B, Pérez-Méndez LI, Santiago F, Rosales B, Servitje O, Estrach T, Fernández-Guarino M, Calzado L, Acebo E, Gallardo F, Salar A, Izu R, Ortiz-Romero PL, Pujol RM, Fernández-de-Misa R. Intralesional rituximab in the treatment of indolent primary cutaneous B-cell lymphomas: an epidemiological observational multicentre study. The Spanish Working Group on Cutaneous Lymphoma. *Br J Dermatol* 2012; **167**: 174-179 [PMID: 22356294 DOI: 10.1111/j.1365-2133.2012.10902.x]

40 **Senff NJ**, Hoefnagel JJ, Jansen PM, Vermeer MH, van Baarlen J, Blokx WA, Canninga-van Dijk MR, Geerts ML, Hebeda KM, Kluin PM, Lam KH, Meijer CJ, Willemze R. Reclassification of 300 primary cutaneous B-Cell lymphomas according to the new WHO-EORTC classification for cutaneous lymphomas: comparison with previous classifications and identification of prognostic markers. *J Clin Oncol* 2007; **25**: 1581-1587 [PMID: 17353548]

41 **Grange F**, Beylot-Barry M, Courville P, Maubec E, Bagot M, Vergier B, Souteyrand P, Machet L, Dalac S, Esteve E, Templier I, Delaporte E, Avril MF, Robert C, Dalle S, Laroche L, Delaunay M, Joly P, Wechsler J, Petrella T. Primary cutaneous diffuse large B-cell lymphoma, leg type: clinicopathologic features and prognostic analysis in 60 cases. *Arch Dermatol* 2007; **143**: 1144-1150 [PMID: 17875875]

42 **Pham-Ledard A**, Prochazkova-Carlotti M, Andrique L, Cappellen D, Vergier B, Martinez F, Grange F, Petrella T, Beylot-Barry M, Merlio JP. Multiple genetic alterations in primary cutaneous large B-cell lymphoma, leg type support a common lymphomagenesis with activated B-cell-like diffuse large B-cell lymphoma. *Mod Pathol* 2014; **27**: 402-411 [PMID: 24030746 DOI: 10.1038/modpathol.2013.156]

43 **Grange F**, Petrella T, Beylot-Barry M, Joly P, D'Incan M, Delaunay M, Machet L, Avril MF, Dalac S, Bernard P, Carlotti A, Esteve E, Vergier B, Dechelotte P, Cassagnau E, Courville P, Saiag P, Laroche L, Bagot M, Wechsler J. Bcl-2 protein expression is the strongest independent prognostic factor of survival in primary cutaneous large B-cell lymphomas. *Blood* 2004; **103**: 3662-3668 [PMID: 14726400]

44 **Pham-Ledard A**, Beylot-Barry M, Barbe C, Leduc M, Petrella T, Vergier B, Martinez F, Cappellen D, Merlio JP, Grange F. High Frequency and Clinical Prognostic Value of MYD88 L265P Mutation in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg-Type. *JAMA Dermatol* 2014; **150**: 1173-1179 [PMID: 25055137 DOI: 10.1001/jamadermatol.2014.821]

45 **Grange F**, Bekkenk MW, Wechsler J, Meijer CJ, Cerroni L, Bernengo M, Bosq J, Hedelin G, Fink Puches R, van Vloten WA, Joly P, Bagot M, Willemze R. Prognostic factors in primary cutaneous large B-cell lymphomas: a European multicenter study. *J Clin Oncol* 2001; **19**: 3602-3610 [PMID: 11504742]

46 **Carroll TJ**, Schelper RL, Goeken JA, Kemp JD. Neoplastic angioendotheliomatosis: immunopathologic and morphologic evidence for intravascular malignant lymphomatosis. *Am J Clin Pathol* 1986; **85**: 169-175 [PMID: 3511672]

47 **Ferreri AJ**, Campo E, Seymour JF, Willemze R, Ilariucci F, Ambrosetti A, Zucca E, Rossi G, López-Guillermo A, Pavlovsky MA, Geerts ML, Candoni A, Lestani M, Asioli S, Milani M, Piris MA, Pileri S, Facchetti F, Cavalli F, Ponzoni M. Intravascular lymphoma: clinical presentation, natural history, management and prognostic factors in a series of 38 cases, with special emphasis on the 'cutaneous variant'. *Br J Haematol* 2004; **127**: 173-183 [PMID: 15461623]

48 **Higashi Y**, Kawai K, Yonekura K, Takeda K, Kanzaki T, Utsunomiya A, Kanekura T. Indication for random skin biopsy for the diagnosis of intravascular large B cell lymphoma. *Dermatology* 2012; **224**: 46-50 [PMID: 22414723]

**P-Reviewer:** MacLeod RAF, Negosanti L, Palmirotta R, Sugimoto KJ **S-Editor:** Ji FF **L-Editor: E-Editor:**



**Figure 1 Primary cutaneous B-cell lymphoma. Red–brown nodules scattered on the trunk.**



**Figure 2 Widespread lymphoid infiltration with clusters of mononuclear cells involving the dermis (HE, × 10).**



**Figure 3 (A–C) Immunophenotype of lymphoid cells: Immunohistochemical staining shows expression of CD20 (A), CD10 (B), and Bcl-6 (C) (Original magnifications × 20).**

**Table 1 World Health Organization and European Organization of Research and Treatment of Cancer classification of primary cutaneous B cell lymphoma (2005)**

|  |
| --- |
| Primary cutaneous B cell Lymphoma |
| Primary cutaneous marginal zone B cell lymphoma |
| Primary cutaneous follicle center lymphoma |
| Primary cutaneous diffuse large B cell lymphoma, leg type |
| Primary cutaneous diffuse large B cell lymphoma, other |
| Intravascular large B cell lymphoma |

**Table 2 International Society for Cutaneous Lymphomas and EORTC TNM staging for cutaneous lymphomas other than mycosis fungoides and Sezary syndrome**

|  |
| --- |
| T |
| T1: Solitaryskininvolvement T1a: a solitary lesion less than 5cm diameterT1b: a solitary lesion greater than 5cm diameter T2: Regional skin involvementT2a: all disease in a 15-cm-diameter circular area T2b: all disease in a 15 and 30 cm diameter circular area T2c: all disease in a 30-cm-diameter circular areaT3: Generalized skin involvement T3a: multiple lesions involving 2 noncontiguous body regions T3b: multiple lesions involving 3 or more body regions |
| N |
| N1: Involvement of 1 peripheral lymph node region that drains an area of current or prior skin involvement N2: Involvement of 2 or more peripheral lymph node regions or involvement of any lymph node region that does not drain an area of current or prior skin involvement N3: Involvement of central lymph nodes |
| M |
| M0: No evidence of extra-cutaneous disease (other than lymph node)M1: Extracutaneous disease is present (other than lymph node) |
|  |